

Form 144

FORM 144/A

NOTICE OF PROPOSED SALE OF SECURITIES  
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

## 144/A: Filer Information

Filer CIK 0001840315  
Filer CCC XXXXXXXX  
Previous Accession Number Of The Filing 0001968940-23-000001  
Is this a LIVE or TEST Filing?  LIVE  TEST

### Submission Contact Information

Name  
Phone  
E-Mail Address

## 144/A: Issuer Information

Name of Issuer EyePoint Pharmaceuticals, Inc.  
SEC File Number 000-51122  
Address of Issuer 480 PLEASANT STREET  
SUITE B300  
WATERTOWN  
MASSACHUSETTS  
02472  
Phone 617-926-5000  
Name of Person for Whose Account the Securities are To Be Sold Ocumension Therapeutics

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Director

## 144/A: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Tiger Brokers (Singapore) Pte. Ltd. Singapore 1 Raffles Place, #35-61 One Raffles, Place Tower 2, Singapore UO 048616	1	5.93	37312647	05/26/2023	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

## 144/A: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	12/31/2020	Through a private placement from the issuer of the securities	Eyepoint Pharmaceuticals, Inc.	<input type="checkbox"/>		3010722	12/31/2020	Good funds

\* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

## 144/A: Securities Sold During The Past 3 Months

Nothing to Report

## 144/A: Remarks and Signature

Remarks This Form 144/A is being filed to amend the Form 144 filed on May 26, 2023 to change (i) the Number of Shares or Other Units to Be Sold from 3010722 to 1, (ii) the Aggregate Market Value from 17853581.46 to 5.93 and (iii) the Number of Shares or Other Units Outstanding from 34301926 to 37312647.

Date of Notice 05/26/2023

### **ATTENTION:**

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature YE LIU

**ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)**